
09/03/2025
Early variation in circulating tumor DNA (ctDNA) can predict long-term progression-free and overall survival in patients with dMMR/MSI-H metastatic colorectal cancer treated with immune checkpoint inhibitors. https://ja.ma/45JA8ze
JAMA Oncology is a member of the JAMA Network, a consortium of peer-reviewed publications.
330 N Wabash Avenue
Chicago, IL
60611
Be the first to know and let us send you an email when JAMA Oncology posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.